First Agili-C™ Cartilage Repair Implantation Procedure in Texas

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the first implantation of the Agili-C™ implant, as part of Investigational Device Exemption (IDE) clinical study by Joseph M. Berman, MD at Arlington Orthopedics Associates (AOA), Arlington, TX.

Arlington Orthopedics Associates is one of 15 U.S. clinical sites participating in this randomized and controlled IDE clinical study. The primary study objective is to demonstrate the superiority of the Agili-C™ implant over the current surgical standards of care: microfracture and debridement in the treatment of large spectrum cartilage defects.

“I have been waiting to begin this important clinical study, because the Agili-C™ implant will potentially allow me to address a growing group of active patients with early to moderate arthritis, which currently lacks good treatment options.

Our first patient was a 30-year-old male with two large cartilage defects and a total surface area of 6cm. One defect was located in the trochlea notch under the patella (knee cap) and the second defect was located on the lateral femoral condyle. The patient was randomized to the Agili-C™ treatment arm and was treated with 3 implants. We were pleased that the patient was randomized to the Agili-C™ treatment arm due to the potential advantage of these implants to reconstitute the articular cartilage and the underlying bone, and as such, decreasing and possibly avoiding the future need of a knee replacement,” said Dr. Berman. “We are impressed with the simplicity of the surgical technique and we continue to identify patients to enroll in the clinical study,” Dr. Berman concluded.

CartiHeal founder and CEO Nir Altschuler stated: “Dr. Berman’s first Agili-C™ implant case in the study provides a great example for a patient who can potentially benefit from the technology we’ve developed, assuming we can demonstrate its superiority over the current surgical standards of care: microfracture and debridement. With 234 patients already enrolled we are expecting to perform an interim analysis later this year, once the remaining 16 study patients are enrolled.”



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.